VIROMED MEDICAL AG

VIROMED MEDICAL AG’s 2026 Xetra performance shows a resilient 5.7 EUR close after a 52‑week low of 2.6 EUR, driven by R&D‑focused innovation in healthcare.

VIROMED Medical AG shows a resilient rebound in stock price and strategic moves amid healthcare sector volatility, spotlighting new growth prospects for investors.

VIROMED MEDICAL AG

Viromed Medical AG launches OEM ViroCAP® for podiatry partner RUCK, expanding cold‑plasma therapy into 120k+ EU clinics and boosting diversified growth.

Viromed Medical AG’s share price rebounded from €2.6 to €8.45 in a year, driven by its innovation‑focused strategy and strong market cap of €67.6 m.

Viromed Medical AG’s manager‑sale spurs a 4.9 % share rally, showcasing executive transparency and hinting at future upside.

Viromed Medical AG is reshaping diagnostics, therapeutics, and cold‑plasma tech. Learn how its innovative products and growth drive the future of healthcare.

Viromed Medical AG’s €6.60 stock reflects biotech volatility—52‑week high €8.45, low €1.62, €67.6M cap—showing investor risk, opportunity, and future potential.

Viromed Medical AG’s €6.00 stock shows sharp volatility—mid‑point between a €8.45 peak and €1.62 low—while awaiting new data on its cold‑plasma‑based lung therapy.

Viromed Medical AG teases breakthrough cold‑plasma therapy for lung care, amid sharp stock swings; investors eye February press conference for next‑step insights.